Pulse Biosciences posts updated investor deck
Pulse Biosciences, Inc. furnished an updated investor presentation dated March 2026, which has been posted on its website and attached as Exhibit 99.1.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Pulse Biosciences, Inc. furnished an updated investor presentation dated March 2026, which has been posted on its website and attached as Exhibit 99.1. The deck includes summary financial information, details on the next-generation nPulse cardiac catheter under development, and an increased focus on EP cardio ablation products and clinical development following what it describes as unprecedented clinical outcomes data from its EU feasibility study.
The company plans to use this investor presentation, in whole or in part and potentially with modifications, in meetings with investors, analysts, and others. The information is provided under a Reg FD disclosure, is considered "furnished" rather than "filed," and includes forward-looking statements that are subject to risks and uncertainties referenced in the company’s SEC filings.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pulse Biosciences (PLSE) disclose in its latest 8-K filing?
Pulse Biosciences disclosed that it furnished an updated March 2026 investor presentation. The deck includes summary financial information, highlights development of its next-generation nPulse cardiac catheter, and emphasizes a stronger focus on EP cardio ablation following unprecedented outcomes in an EU feasibility study.
What is included in Pulse Biosciences’ March 2026 investor presentation?
The March 2026 investor presentation includes summary financial information and a description of Pulse Biosciences’ next-generation nPulse cardiac catheter under development. It also outlines a strengthened focus on EP cardio ablation products and clinical development after unprecedented clinical outcomes in the company’s EU feasibility study.
How will Pulse Biosciences (PLSE) use the updated investor deck?
Pulse Biosciences expects to use the updated investor deck, in whole or in part and possibly with modifications, in presentations to investors, analysts, and others. This makes the deck a key communication tool for explaining its technology, financial summary information, and strategic clinical focus.
Where can investors access Pulse Biosciences’ new investor presentation?
Investors can access Pulse Biosciences’ updated March 2026 investor presentation as Exhibit 99.1 to the 8-K and on the company’s website at www.pulsebiosciences.com under “Investors.” The filing specifies that, aside from the deck, website information is not incorporated by reference.
Does the Pulse Biosciences investor deck contain forward-looking statements?
Yes. The company states that the investor deck contains forward-looking statements subject to risks and uncertainties. These risks include those described in Pulse Biosciences’ SEC filings, and the company does not undertake to update the information in the deck or the related disclosure except as required by law.
Is Pulse Biosciences’ March 2026 investor deck considered filed with the SEC?
No. The company specifies that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for purposes of Section 18 of the Exchange Act. As a result, it is not automatically subject to Section 18 liabilities or incorporated into other SEC filings unless expressly stated.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 3, 2026
|
|
||
|
(Exact Name of Registrant as Specified in Its Charter)
|
||
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
||
|
(Address of Principal Executive Offices) (Zip Code)
|
||
| (Registrant’s Telephone Number, Including Area Code) | ||
|
Not Applicable
|
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure.
|
On March 3, 2026, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), posted an updated investor presentation on its website. The updated investor presentation (the “Investor Deck”) discloses, among other things, certain summary financial information for the Company, a description of its next generation nPulse cardiac catheter under development, as well as strengthened "focus on EP cardio ablation product and clinical development following unprecedented clinical outcomes data in . . . [the Company's] EU feasibility study." The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company’s website at www.pulsebiosciences.com under “Investors.”
Except for the Investor Deck, information contained on, or accessible through, the Company’s website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company’s filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of March 2026, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.
The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
| Exhibit Number | Description |
| 99.1 | Investor Deck, dated March 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
PULSE BIOSCIENCES, INC.
|
|||
|
Date: March 3, 2026
|
By:
|
/s/ Paul A. LaViolette
|
|
|
Paul A. LaViolette
|
|||
|
Chief Executive Officer
(Principal Executive Officer) |
|||
Exhibit 99.1 - Investor Presentation March 2026
